Adma Biologics (ADMA) Income towards Parent Company (2011 - 2025)

Adma Biologics' Income towards Parent Company history runs 13 years deep, the most recent figure standing at -$133.3 million for Q4 2025.

• Quarterly Income towards Parent Company fell 367.26% year-over-year to -$133.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.7 million (down 126.34% YoY) and the FY2025 annual result came in at -$35.7 million, down 126.34% from the prior year.
• Income towards Parent Company was -$133.3 million for Q4 2025 at Adma Biologics, down from $36.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $49.9 million in Q4 2024 and bottomed at -$133.3 million in Q4 2025.
• A 5-year average of -$2.3 million and a median of -$6.6 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company surged 1299.96% — and 2025, when it sank 367.26%.
• Adma Biologics' Income towards Parent Company stood at -$25.1 million in 2021, then rose by 25.89% to -$18.6 million in 2022, then surged by 156.85% to $10.6 million in 2023, then jumped by 370.72% to $49.9 million in 2024, then plunged by 367.26% to -$133.3 million in 2025.
• Business Quant data shows ADMA's Income towards Parent Company at -$133.3 million in Q4 2025, $36.4 million in Q3 2025, and $34.2 million in Q2 2025.